{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:25:25Z","timestamp":1778876725090,"version":"3.51.4"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EJR"],"abstract":"<jats:p>Abstract\n\t\u00a0\n\n\tCheckpoint inhibitors are a novel option in the management of metastatic melanomas and many other malignancies. They are used to promote the activation of cytotoxic T-lymphocytes by inhibiting deactivation signals, enabling the immune response to the tumor. Numerous Immune-related adverse effects caused by checkpoint inhibitors have been reported in the literature. They are diverse in nature, and many are life threatening. We report a case of autoimmune myositis and myasthenia gravis following treatment with a combination of ipilimumab and nivolumab for metastatic melanoma.\n\n\t\u00a0\n\n\t\u00a0\n\n\tCite this article as: Sutaria R, Patel P, Danve A. Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma. Eur J Rheumatol 2019; 6(3): 153-4.<\/jats:p>","DOI":"10.5152\/eurjrheum.2019.18159","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T03:59:25Z","timestamp":1554955165000},"page":"153-154","source":"Crossref","is-referenced-by-count":8,"title":["Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma"],"prefix":"10.5152","volume":"6","author":[{"given":"Ravi","family":"Sutaria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parit","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijeet","family":"Danve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3111","published-online":{"date-parts":[[2019,9,3]]},"container-title":["European Journal of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/download\/329\/329","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:24:49Z","timestamp":1753773889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/view\/329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9,3]]}},"URL":"https:\/\/doi.org\/10.5152\/eurjrheum.2019.18159","relation":{},"ISSN":["2148-4279"],"issn-type":[{"value":"2148-4279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]}}}